SCHEMBL5523487

SCHEMBL5523487

CN1CCN(c2ccc3nc(-c4cc(-c5ccc(N)cc5)n[nH]4)[nH]c3c2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
TOP1 P11387 3/20 0.57
TOP2A P11388 3/20 0.57
HPGD P15428 1/20 0.57
HSD17B10 Q99714 1/20 0.57
FGFR1 P11362 6/20 0.54
TERT O14746 2/20 0.54
FLT1 P17948 2/20 0.54
KDR P35968 5/20 0.54
PDGFRB P09619 4/20 0.54
MELK Q14680 1/20 0.54
MEN1 O00255 2/20 0.53
MAPT P10636 2/20 0.53
BLM P54132 2/20 0.53
KMT2A Q03164 2/20 0.53
KDM4E B2RXH2 2/20 0.53
GAA P10253 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
SLCO2B1 O94956 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3843474 0.82 ACHE (0.53) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14342671 0.77 BRD4 (0.48) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL933054 0.77 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL31006250 0.76 FGFR1 (0.76) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL3535921 0.76 FGFR1 (0.76) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL3542379 0.76 FGFR1 (0.76) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL5528791 0.76 RAF1 (0.51) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL3842984 0.75 SMN1; SMN2 (0.64) ALDH1A1SMN1; SMN2HPGDHSD17B10MEN1
SCHEMBL14656343 0.74 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14399402 0.74 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710038-B2 Pyrazole kinase modulators and methods of use EXELIXIS, INC. (US) 2014-04-29 US disclosed
US-8710038-B2 Pyrazole kinase modulators and methods of use EXELIXIS, INC. (US) 2014-04-29 US disclosed
US-8710038-B2 Pyrazole kinase modulators and methods of use EXELIXIS, INC. (US) 2014-04-29 US disclosed
US-20070293507-A1 Pyrazole Kinase Modulators And Methods Of Use EXELIXIS, INC. (US) 2007-12-20 US disclosed
US-20070293507-A1 Pyrazole Kinase Modulators And Methods Of Use EXELIXIS, INC. (US) 2007-12-20 US disclosed
US-20070293507-A1 Pyrazole Kinase Modulators And Methods Of Use EXELIXIS, INC. (US) 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293507-A1 Pyrazole Kinase Modulators And Methods Of Use MAP3K1, MAP3K3, MAP3K5 ALDH1A1 3244/4885SMN1; SMN2 4604/4885TOP1 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.